Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study

• Published in: Blood 2010-11, Vol.116 (21), p.440-440
• Main Authors: de Renzis, Benoit, Wattel, Eric, Beyne-Rauzy, Odile, Knoops, Laurent, Boyer, Françoise, Cabrespine, Aurélie, Raynaud, Sophie, Rose, Christian, Demory, Jean-Loup, Nguyen-Khac, Florence, Ades, Lionel, Tertian, Gerard, Guièze, Romain, Christophe Ianotto, Jean, Tournilhac, Olivier, Bordessoule, Dominique, Cahn, Jean-Yves, Fontenay, Michaela, Kiladjian, Jean-Jacques, Fenaux, Pierre
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V116.21.440.440

Abstract 440 The JAK2V617F mutation is found in a small proportion of MDS, especially in RARS-T and occasionally in other MDS subtypes, but the overall impact of JAK2V617F on MDS characteristics and outcome remains unclear. Diagnostic and follow up data on MDS patients (pts) with known JAK2V617F mutation status were collected from 19 centers of the Groupe Francophone des Myélodysplasies (GFM) and the French Intergroup of MPN (FIM). MDS post MPN and CMML were excluded. Patient characteristics and outcome according to JAK2V617F status were analyzed by univariate analysis. Survival analysis with Cox model matched on age, IPSS score and sex according to JAK2 status was also made. Analysis was performed using STATA 10.0 software. 161 cases were collected, including 65 JAK2V617F mutated (JAK2 pos) and 96 unmutated (JAK2 neg) cases. Median age was 75 years and M/F ratio 1.2 in JAK2 pos vs 71 years (p=NS) and 1 (p=NS) in JAK2 neg pts, respectively (resp). WHO 2008 distribution was RA (8%), RARS (12%), RARS-T (41%), CRDM (15%), RAEB-1 (11%), RAEB-2 (5%), 5q- (3%), unclassified (5%) in JAK2 pos pts and RA (25%), RARS (9%), RARS-T (1%), CRDM (14%), RAEB-1 (28%), RAEB-2 (19%), 5q- (1%), unclassified (3%) in JAK2 neg pts, resp (p